358 related articles for article (PubMed ID: 34476650)
61. Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes.
Hu C; LaDuca H; Shimelis H; Polley EC; Lilyquist J; Hart SN; Na J; Thomas A; Lee KY; Davis BT; Black MH; Pesaran T; Goldgar DE; Dolinsky JS; Couch FJ
JCO Precis Oncol; 2018; 2():. PubMed ID: 31497750
[TBL] [Abstract][Full Text] [Related]
62. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.
Kuzbari Z; Bandlamudi C; Loveday C; Garrett A; Mehine M; George A; Hanson H; Snape K; Kulkarni A; Allen S; Jezdic S; Ferrandino R; Westphalen CB; Castro E; Rodon J; Mateo J; Burghel GJ; Berger MF; Mandelker D; Turnbull C
Ann Oncol; 2023 Mar; 34(3):215-227. PubMed ID: 36529447
[TBL] [Abstract][Full Text] [Related]
63. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer.
Goldstein JB; Zhao L; Wang X; Ghelman Y; Overman MJ; Javle MM; Shroff RT; Varadhachary GR; Wolff RA; McAllister F; Futreal A; Fogelman DR
Clin Cancer Res; 2020 Mar; 26(6):1385-1394. PubMed ID: 31871297
[TBL] [Abstract][Full Text] [Related]
64. No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma.
Grützmann R; McFaul C; Bartsch DK; Sina-Frey M; Rieder H; Koch R; McCarthy E; Greenhalf W; Neoptolemos JP; Saeger HD; Pilarsky C
Cancer Lett; 2004 Oct; 214(1):63-8. PubMed ID: 15331174
[TBL] [Abstract][Full Text] [Related]
65. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
[TBL] [Abstract][Full Text] [Related]
66. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
[TBL] [Abstract][Full Text] [Related]
67. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
68. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
[TBL] [Abstract][Full Text] [Related]
69. Identification of Germline Variants in Patients with Hereditary Cancer Syndromes in Northeast Mexico.
Pérez-Ibave DC; Garza-Rodríguez ML; Noriega-Iriondo MF; Flores-Moreno SM; González-Geroniz MI; Espinoza-Velazco A; Castruita-Ávila AL; Alcorta-Núñez F; Zayas-Villanueva OA; González-Guerrero JF; Alcorta-Garza A; Vidal-Gutiérrez O; Burciaga-Flores CH
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833268
[TBL] [Abstract][Full Text] [Related]
70. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
[TBL] [Abstract][Full Text] [Related]
71. Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes.
Gardiner A; Kidd J; Elias MC; Young K; Mabey B; Taherian N; Cummings S; Malafa M; Rosenthal E; Permuth JB
J Natl Cancer Inst; 2022 Jul; 114(7):996-1002. PubMed ID: 35445726
[TBL] [Abstract][Full Text] [Related]
72. A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
de Souza Timoteo AR; Gonçalves AÉMM; Sales LAP; Albuquerque BM; de Souza JES; de Moura PCP; de Aquino MAA; Agnez-Lima LF; Lajus TBP
Breast Cancer Res Treat; 2018 Dec; 172(3):637-646. PubMed ID: 30159786
[TBL] [Abstract][Full Text] [Related]
73. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
[TBL] [Abstract][Full Text] [Related]
74. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
75. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
[TBL] [Abstract][Full Text] [Related]
76. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
Pearlman R; Frankel WL; Swanson B; Zhao W; Yilmaz A; Miller K; Bacher J; Bigley C; Nelsen L; Goodfellow PJ; Goldberg RM; Paskett E; Shields PG; Freudenheim JL; Stanich PP; Lattimer I; Arnold M; Liyanarachchi S; Kalady M; Heald B; Greenwood C; Paquette I; Prues M; Draper DJ; Lindeman C; Kuebler JP; Reynolds K; Brell JM; Shaper AA; Mahesh S; Buie N; Weeman K; Shine K; Haut M; Edwards J; Bastola S; Wickham K; Khanduja KS; Zacks R; Pritchard CC; Shirts BH; Jacobson A; Allen B; de la Chapelle A; Hampel H;
JAMA Oncol; 2017 Apr; 3(4):464-471. PubMed ID: 27978560
[TBL] [Abstract][Full Text] [Related]
77.
Rosen MN; Goodwin RA; Vickers MM
World J Gastroenterol; 2021 May; 27(17):1943-1958. PubMed ID: 34007132
[TBL] [Abstract][Full Text] [Related]
78. Germline mutations in pancreatic cancer and potential new therapeutic options.
Pihlak R; Valle JW; McNamara MG
Oncotarget; 2017 Sep; 8(42):73240-73257. PubMed ID: 29069866
[TBL] [Abstract][Full Text] [Related]
79. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions.
Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313
[TBL] [Abstract][Full Text] [Related]
80. Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients with Pancreatic Cancer or Suspected Related Hereditary Syndromes: Historical Prospective Analysis.
Dal Buono A; Poliani L; Greco L; Bianchi P; Barile M; Giatti V; Bonifacio C; Carrara S; Malesci A; Laghi L
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
